Shares of Glaukos Corporation (GKOS, Financial) declined in the first quarter as a result of the massive correction in the biotech/pharma space. Glaukos, which manufactures stents to relieve glaucoma pressure, expects 26% to 30% growth in 2016, which we think will drive revenue to $90 millin to $93 million. While major label expansion to deliver Glaukos’ iStents without cataract surgery (current FDA approval) is still some years away, we retain conviction because of the growth opportunity presented by the rising incidence of glaucoma as a result of the aging U.S. population.
From the Baron Global Advantage Fund first quarter 2016 commentary.
